However, evidence shows imatinib is unable to fully inactivate BCR-ABL signals [36] and a number of patients are resistant to this therapy [37], highlighting the need to further understand the biology of CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.